Noida Chronicle

Creative Biolabs: Supporting Virus Research with Full Impetus

 Breaking News
  • No posts were found

Creative Biolabs: Supporting Virus Research with Full Impetus

April 19
17:27 2023
Creative Biolabs, gearing up for upcoming exhibition events in May and June, has just announced upgrades to its solutions to help studies on developing the best approaches against the rising health challenges facing the global community.

New York, USA – April 19, 2023 – With two critical exhibitions in the second season under intense preparation, Creative Biolabs, one of the reliable CROs, has recently updated its service scope and looks forward to meeting industry participants in the forthcoming networking conferences-PEGS in May and the 2023 BIO International Convention, which will highlight advances in biotech and immuno-oncology fields.

“We’ve been through serious disease concerns like Omicron, Zika, and monkeypox, but 2022 was a successful year anyway. We are in an urgent status to find potent measurements accordingly,” according to a specialist at Creative Biolabs, “and that’s why we’re stretching our service and product scope, to encompass those innovative therapeutics.”

This time the updates involve the very part concerning therapeutics against virus infection, including vaccine and mRNA therapeutics.

A suite of services was issued exclusively for virology, including virus antibody discovery and engineering, virology testing, and neutralization assay, aiming to provide omni-directional solutions to facilitate customer’s projects. Features of these services are highlighted below.

* Antibody discovery platforms: phage display, B cell sorting, Hyperdoma™, yeast display, etc.

* Virology testing capabilities: viral load quantification, antiviral assays

* Neutralization assays: ELISA-based receptor-binding inhibition assay, FC-based receptor-binding inhibition assay, pseudovirus neutralization assay

An effective measure to curb virus spread is vaccine, for which Creative Biolabs has also made some improvements.

“We’ve updated our catalog of antibody products for vaccine development,” said the scientist, “to encompass almost every threat to human health, covering tricky targets like Zika, HBV, and HIV.” Those antibodies, developed utilizing hybridoma or recombinant DNA tactics, stand out with their superior specificity and purity, contribute to the development of vaccines for preventive and therapeutic purposes.

With the first COVID-19 vaccine successfully approved for use in humans, mRNA vaccines achieved instant fame. Creative Biolabs set up a studio exclusively for mRNA-based solutions, including mRNA chemical synthesis, mRNA modification, and mRNA validation.

A newly released news report from the WTO reveals unprecedented unity among the entire health community, which has just found some relief from the shock brought by the global pandemic-COVID-19. Yet the journey towards an optimal status in precision medicine is arduous, but the bursting breakthroughs in academia symbolize a promising future. Creative Biolabs is determined to work arduously with its new drug R&D-oriented solutions to support academic and industry research.

Visit to learn more about the event arrangements and capabilities at Creative Biolabs.


Creative Biolabs is a biotechnology company with over a decade of experience serving projects concerning new therapy development and disease studies. The forthcoming exhibition of Creative Biolabs-PEGS-is taking place shortly in Boston, May 2023.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States

Related Articles